Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity

Biochemical and Biophysical Research Communications

Volumn 386, Issue 1, 2009, Pages 16-20

  Nath, Narender ^a   Khan, Musfiquidin ^a   Rattan, Ramandeep ^b   Mangalam, Ashutosh ^c   Makkar, Randhir S ^a   Meester, Carloe de ^d   Bertrand, Luc ^d   Singh, Inderjit ^a   Chen, Yingjie ^e   Viollet, Benoit ^f,g   Giri, Shailendra ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MAYO CLINIC   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

^d UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^e UNIVERSITY OF MINNESOTA   (United States)

^f INSTITUT COCHIN   (France)

^g INSERM   (France)

Author keywords

AMPK; EAE; Macrophage; Multiple sclerosis; T cells

Indexed keywords

GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISEASE SEVERITY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; MACROPHAGE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; T LYMPHOCYTE; WILD TYPE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DOWN-REGULATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ISOENZYMES; MALE; MICE; MICE, MUTANT STRAINS; PROTEIN SUBUNITS; SPLEEN;

ANIMALIA; MAMMALIA; MUS;

EID: 67649229607     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.05.106     Document Type: Article

References (23)

1. Hardie D.G. AMP-activated protein kinase as a drug target. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 185-210
2. Hardie D.G., Salt I.P., Hawley S.A., and Davies S.P. AMP-activated protein kinase: an ultrasensitive system for monitoring cellular energy charge. Biochem. J. 338 Pt 3 (1999) 717-722
3. Hardie D.G., Scott J.W., Pan D.A., and Hudson E.R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 546 (2003) 113-120
4. Hong S.P., Leiper F.C., Woods A., Carling D., and Carlson M. Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc. Natl. Acad. Sci. USA 100 (2003) 8839-8843
5. Hong S.P., Momcilovic M., and Carlson M. Function of mammalian LKB1 and Ca2+/calmodulin-dependent protein kinase kinase alpha as Snf1-activating kinases in yeast. J. Biol. Chem. 280 (2005) 21804-21809
6. Momcilovic M., Hong S.P., and Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J. Biol. Chem. 281 (2006) 25336-25343
7. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23 (2005) 683-747
8. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group, Neurology 43 (1993) 655-661.
9. Hartung H.P., Gonsette R., Konig N., Kwiecinski H., Guseo A., Morrissey S.P., Krapf H., and Zwingers T. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360 (2002) 2018-2025
10. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., Myers L.W., Panitch H.S., Rose J.W., and Schiffer R.B. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial, The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45 (1995) 1268-1276
11. Filippini G., Munari L., Incorvaia B., Ebers G.C., Polman C., D'Amico R., and Rice G.P. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361 (2003) 545-552
12. Munari L.M., and Filippini G. Lack of evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurol. 3 (2004) 641
13. Jorgensen S.B., Wojtaszewski J.F., Viollet B., Andreelli F., Birk J.B., Hellsten Y., Schjerling P., Vaulont S., Neufer P.D., Richter E.A., and Pilegaard H. Effects of alpha-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle. FASEB J. 19 (2005) 1146-1148
14. R. Mounier, L. Lantier, J. Leclerc, A. Sotiropoulos, M. Pende, D. Daegelen, K. Sakamoto, M. Foretz, B. Viollet, Important role for AMPK{alpha}1 in limiting skeletal muscle cell hypertrophy, FASEB J. (2009).
15. Viollet B., Andreelli F., Jorgensen S.B., Perrin C., Geloen A., Flamez D., Mu J., Lenzner C., Baud O., Bennoun M., Gomas E., Nicolas G., Wojtaszewski J.F., Kahn A., Carling D., Schuit F.C., Birnbaum M.J., Richter E.A., Burcelin R., and Vaulont S. The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J. Clin. Invest. 111 (2003) 91-98
16. Nath N., Khan M., Paintlia M.K., Hoda Md.N., and Giri S. Metformin attenuated the autoimmune disease of central nervous system in animal models of Multiple Sclerosis. J. Immunol. 182 (2009) 8005-8014
17. Giri S., Khan M., Nath N., Singh I., and Singh A.K. The role of AMPK in psychosine mediated effects on oligodendrocytes and astrocytes: implication for Krabbe disease. J. Neurochem. 105 (2008) 1820-1833
18. Vincent M.F., Marangos P.J., Gruber H.E., and Van den Berghe G. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes 40 (1991) 1259-1266
19. Al-Hakim A.K., Zagorska A., Chapman L., Deak M., Peggie M., and Alessi D.R. Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-linked polyubiquitin chains. Biochem. J. 411 (2008) 249-260
20. J. Qi, J. Gong, T. Zhao, J. Zhao, P. Lam, J. Ye, J.Z. Li, J. Wu, H.M. Zhou, P. Li, Downregulation of AMP-activated protein kinase by Cidea-mediated ubiquitination and degradation in brown adipose tissue, EMBO J. (2008).
21. Tamas P., Hawley S.A., Clarke R.G., Mustard K.J., Green K., Hardie D.G., and Cantrell D.A. Regulation of the energy sensor AMP-activated protein kinase by antigen receptor and Ca2+ in T. lymphocytes. J. Exp. Med. 203 (2006) 1665-1670
22. Ziemssen T., and Ziemssen F. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Autoimmun. Rev. 4 (2005) 460-467
23. Mayer A., Denanglaire S., Viollet B., Leo O., and Andris F. AMP-activated protein kinase regulates lymphocyte responses to metabolic stress but is largely dispensable for immune cell development and function. Eur. J. Immunol. 38 (2008) 948-956